(MRK) Merck - Ratings and Ratios
Keytruda, Gardasil, Januvia, Bovilis, Bravecto
MRK EPS (Earnings per Share)
MRK Revenue
Description: MRK Merck
Merck & Co., Inc. (ticker MRK) is a U.S.–based, globally operating healthcare company founded in 1891 and headquartered in Rahway, New Jersey, with business segments in human pharmaceuticals and animal health.
Its human-health portfolio spans oncology (Keytruda, Welireg, Zerbaxa, Noxafil), vaccines (Gardasil, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23), and chronic-disease therapies (Januvia/Janumet, Belsomra, Isentress, Adempas, Verquvo, Lagevrio, among others).
The animal-health division offers livestock products (Nuflor, Bovilis, Banamine, etc.) and companion-animal medicines (Bravecto, Sentinel, Nobivac, etc.), complemented by Allflex Livestock Intelligence digital solutions.
Merck maintains a network of strategic collaborations, including three deruxtecan ADC candidates with Daiichi Sankyo, co-development of Lynparza and Koselugo with AstraZeneca, licensing of the LM-299 bispecific antibody from LaNova, and partnerships with Eisai, Bayer, Ridgeback, Moderna, and Antengene to expand its oncology and immunotherapy pipeline.
Key financial and sector metrics: FY 2023 revenue reached approximately $59.3 billion, with Keytruda alone generating roughly $13 billion; R&D expenditure was about $9.5 billion (≈16 % of sales); animal health contributed ~ $5 billion. Primary growth drivers are an aging global population, rising cancer incidence, and sustained vaccine demand post-COVID-19, while pricing pressure in the U.S. and biosimilar competition pose ongoing risks.
For a deeper quantitative assessment of MRK’s valuation sensitivities and peer-adjusted multiples, the ValueRay platform offers a concise, data-driven dashboard worth exploring.
MRK Stock Overview
| Market Cap in USD | 209,614m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1978-01-13 |
MRK Stock Ratings
| Growth Rating | -15.3% |
| Fundamental | 86.8% |
| Dividend Rating | 67.3% |
| Return 12m vs S&P 500 | -28.2% |
| Analyst Rating | 4.04 of 5 |
MRK Dividends
| Dividend Yield 12m | 3.82% |
| Yield on Cost 5y | 5.06% |
| Annual Growth 5y | 7.16% |
| Payout Consistency | 97.7% |
| Payout Ratio | 42.4% |
MRK Growth Ratios
| Growth Correlation 3m | 45.9% |
| Growth Correlation 12m | -67.5% |
| Growth Correlation 5y | 63.9% |
| CAGR 5y | -1.04% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.02 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.07 |
| Sharpe Ratio 12m | -0.41 |
| Alpha | -29.76 |
| Beta | 0.373 |
| Volatility | 28.87% |
| Current Volume | 10758.9k |
| Average Volume 20d | 11804.2k |
| Stop Loss | 82.2 (-3.1%) |
| Signal | 0.32 |
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (16.41b TTM) > 0 and > 6% of Revenue (6% = 3.82b TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA 0.85pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 17.34% (prev 19.44%; Δ -2.10pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.16 (>3.0%) and CFO 18.53b > Net Income 16.41b (YES >=105%, WARN >=100%) |
| Net Debt (27.39b) to EBITDA (25.04b) ratio: 1.09 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.42 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (2.51b) change vs 12m ago -1.22% (target <= -2.0% for YES) |
| Gross Margin 76.60% (prev 75.25%; Δ 1.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 55.28% (prev 55.47%; Δ -0.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 16.02 (EBITDA TTM 25.04b / Interest Expense TTM 1.28b) >= 6 (WARN >= 3) |
Altman Z'' 4.70
| (A) 0.09 = (Total Current Assets 37.06b - Total Current Liabilities 26.04b) / Total Assets 117.52b |
| (B) 0.58 = Retained Earnings (Balance) 68.48b / Total Assets 117.52b |
| (C) 0.18 = EBIT TTM 20.44b / Avg Total Assets 115.08b |
| (D) 0.95 = Book Value of Equity 64.84b / Total Liabilities 68.46b |
| Total Rating: 4.70 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 86.75
| 1. Piotroski 7.50pt = 2.50 |
| 2. FCF Yield 6.23% = 3.11 |
| 3. FCF Margin 23.14% = 5.79 |
| 4. Debt/Equity 0.72 = 2.25 |
| 5. Debt/Ebitda 1.09 = 1.63 |
| 6. ROIC - WACC (= 15.27)% = 12.50 |
| 7. RoE 34.88% = 2.50 |
| 8. Rev. Trend 67.17% = 5.04 |
| 9. EPS Trend 28.64% = 1.43 |
What is the price of MRK shares?
Over the past week, the price has changed by -1.06%, over one month by +4.02%, over three months by +7.97% and over the past year by -17.31%.
Is Merck a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MRK is around 78.43 USD . This means that MRK is currently overvalued and has a potential downside of -7.5%.
Is MRK a buy, sell or hold?
- Strong Buy: 12
- Buy: 3
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MRK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 101.8 | 20.1% |
| Analysts Target Price | 101.8 | 20.1% |
| ValueRay Target Price | 85.8 | 1.2% |
Last update: 2025-10-18 05:04
MRK Fundamental Data Overview
P/E Trailing = 12.9307
P/E Forward = 9.1324
P/S = 3.295
P/B = 4.5634
P/EG = 0.8012
Beta = 0.373
Revenue TTM = 63.62b USD
EBIT TTM = 20.44b USD
EBITDA TTM = 25.04b USD
Long Term Debt = 33.97b USD (from longTermDebt, last quarter)
Short Term Debt = 1.43b USD (from shortTermDebt, last quarter)
Debt = 35.40b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 27.39b USD (from netDebt column, last quarter)
Enterprise Value = 236.39b USD (209.61b + Debt 35.40b - CCE 8.62b)
Interest Coverage Ratio = 16.02 (Ebit TTM 20.44b / Interest Expense TTM 1.28b)
FCF Yield = 6.23% (FCF TTM 14.72b / Enterprise Value 236.39b)
FCF Margin = 23.14% (FCF TTM 14.72b / Revenue TTM 63.62b)
Net Margin = 25.79% (Net Income TTM 16.41b / Revenue TTM 63.62b)
Gross Margin = 76.60% ((Revenue TTM 63.62b - Cost of Revenue TTM 14.88b) / Revenue TTM)
Gross Margin QoQ = 77.50% (prev 77.98%)
Tobins Q-Ratio = 2.01 (Enterprise Value 236.39b / Total Assets 117.52b)
Interest Expense / Debt = 0.86% (Interest Expense 305.0m / Debt 35.40b)
Taxrate = 11.42% (571.0m / 5.00b)
NOPAT = 18.10b (EBIT 20.44b * (1 - 11.42%))
Current Ratio = 1.42 (Total Current Assets 37.06b / Total Current Liabilities 26.04b)
Debt / Equity = 0.72 (Debt 35.40b / totalStockholderEquity, last quarter 48.99b)
Debt / EBITDA = 1.09 (Net Debt 27.39b / EBITDA 25.04b)
Debt / FCF = 1.86 (Net Debt 27.39b / FCF TTM 14.72b)
Total Stockholder Equity = 47.04b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.96% (Net Income 16.41b / Total Assets 117.52b)
RoE = 34.88% (Net Income TTM 16.41b / Total Stockholder Equity 47.04b)
RoCE = 25.23% (EBIT 20.44b / Capital Employed (Equity 47.04b + L.T.Debt 33.97b))
RoIC = 21.70% (NOPAT 18.10b / Invested Capital 83.41b)
WACC = 6.43% (E(209.61b)/V(245.02b) * Re(7.39%) + D(35.40b)/V(245.02b) * Rd(0.86%) * (1-Tc(0.11)))
Discount Rate = 7.39% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.81%
[DCF Debug] Terminal Value 79.70% ; FCFE base≈14.09b ; Y1≈15.60b ; Y5≈20.30b
Fair Price DCF = 141.2 (DCF Value 352.68b / Shares Outstanding 2.50b; 5y FCF grow 12.34% → 3.0% )
EPS Correlation: 28.64 | EPS CAGR: 5.26% | SUE: 1.55 | # QB: 2
Revenue Correlation: 67.17 | Revenue CAGR: 2.02% | SUE: -0.14 | # QB: 0
Additional Sources for MRK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle